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Novelty and impact statement: Our data challenges the belief that modern medical endocrine treatment is as 
effective as prophylactic surgery for endocrine ablation in breast cancer survivors. If our data can be 
replicated in another independent dataset, hysterectomy plus removal of the ovaries should be considered by 
premenopausal women diagnosed with breast cancer and could reduce their risk of death by 50%. 
Prophylactic surgery does not seem to be of benefit to postmenopausal women diagnosed with breast cancer. 
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Abstract  
Prophylactic surgery including hysterectomy and bilateral salpingo-oophorectomy (BSO) is recommended 
in BRCA positive women, while in women from the general population, hysterectomy plus BSO may 
increase the risk of overall mortality. The effect of hysterectomy plus BSO on women previously diagnosed 
with breast cancer is unknown.  
We used data from a population-base data linkage study of all women diagnosed with primary breast cancer 
in Queensland, Australia between 1997 and 2008 (n=21,067).  We fitted flexible parametric breast cancer 
specific and overall survival models with 95% confidence intervals (also known as Royston-Parmar models) 
to assess the impact of risk-reducing surgery (removal of uterus, one or both ovaries). We also stratified 
analyses by age 20-49 and 50-79 years, respectively. 
Overall, 1,426 women (7%) underwent risk-reducing surgery (13% of premenopausal women and 3% of 
postmenopausal women). No women who had risk-reducing surgery, compared to 171 who did not have 
risk-reducing surgery developed a gynaecological cancer. Overall, 3,165 (15%) women died, including 
2,195 (10%) from breast cancer. Hysterectomy plus BSO was associated with significantly reduced risk of 
death overall (adjusted HR = 0.69, 95% CI 0.53-0.89; P =0.005). Risk reduction was greater among 
premenopausal women, whose risk of death halved (HR, 0.45; 95% CI, 0.25-0.79; P < 0.006). This was 
largely driven by reduction in breast cancer-specific mortality (HR, 0.43; 95% CI, 0.24-0.79; P < 0.006).  
This population-based study found that risk-reducing surgery halved the mortality risk for premenopausal 
breast cancer patients. Replication of our results in independent cohorts, and subsequently randomised trials 
are needed to confirm these findings.  
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Introduction 
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females 
globally, accounting for 23% of total cancer cases and 14% of cancer deaths in 2008 
1
. Breast cancer 
incidence has been rising in Asia and Africa 
2, 3
, while rates have largely stabilised in North America, 
Europe and Australia 
4, 5
, although in young women (25-39 years) an increase in breast cancer with distant 
involvement has been observed (United States SEER data 1996-2009; 
6
). 
Risk factors for breast and uterine cancers are well described and include prolonged exposure to and higher 
concentrations of endogenous estrogen 
7, 8
. Women in Queensland (QLD), Australia (including mutation 
carriers), who were diagnosed with breast cancer subsequently have a more than 150% increased risk of 
developing uterine cancer and also a higher than 40% increased risk of developing ovarian cancer compared 
to the general population 
9
. Risk-reducing  hysterectomy and bilateral salpingo-oophorectomy (BSO) could 
reduce the risk of subsequent gynaecological and breast cancers in these patients.  
In breast cancer susceptibility gene (BRCA) carriers, risk-reducing BSO significantly reduces ovarian 
cancer risk 
10
 and incidence of new breast cancers in premenopausal women 
11-13
. Consequently, in BRCA 
carriers BSO decreases all-cause, breast cancer-specific, and ovarian cancer-specific mortality
11-13
. 
However, only 5 to 6% of all breast cancers are directly attributable to inheritance and the cumulative risk of 
developing breast cancer by age 70 for a mutation carrier in Australia is approximately 40% 
14
, less than had 
been estimated from studies in other countries 
15
. Furthermore, the cumulative risk of ovarian cancer by age 
70 is estimated at 40 to 50% for BRCA1 mutation carriers and 10 to 25% for BRCA2 carriers 
16-19
.  
In women at average cancer risk without a previous diagnosis of breast cancer, two large prospective studies 
and one retrospective population-based cohort study found that hysterectomy plus BSO reduced risk of 
ovarian cancer by more than 96% and the risk of breast cancer in women 45 years or younger by 40% 
20-27
. 
However, these benefits were counteracted by a significantly increased risk of death from other causes (e.g. 
cardiovascular disease) compared with women who preserved their ovaries, particularly among 
premenopausal women. In a meta-analysis of 12 case-control studies and a recent case-control study, 
hysterectomy alone without BSO was reported to reduce the risk of ovarian cancer by 34% 
28
 and breast 
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cancer risk by 16% 
29
, respectively. The exact mechanism of this is unknown but it is suspected to be 
induced by reduced follicle stimulating hormone levels.   
Risk-reducing surgery could potentially form one of the many options in the breast cancer treatment 
armamentarium already complex to a degree that it requires decision making algorithms.Currently, for 
patients diagnosed with breast cancer, the benefits and risks of BSO are unknown, especially for the 
majority (>90%) of patients who are BRCA1/2 negative. We therefore used a population-based data linkage 
approach to examine if patients with a personal history of breast cancer who had risk-reducing BSO with or 
without hysterectomy experienced different overall and breast cancer specific survival compared to women 
with breast cancer who did not have prophylactic gynaecological surgery.  
 
Methods 
Data 
All cases of invasive breast cancer (ICD-O-3 code C50) diagnosed among women 20-79 years, in 
Queensland (QLD) between 1997 and 2008 were selected from the population-based QLD Cancer Registry 
(QCR).  Cases based on autopsy or death certificate only were excluded. Other data items available from the 
QCR included breast cancer cell type (morphology), Indigenous status (self-identified), laterality and size of 
the tumour, number of lymph nodes surgically excised, number of lymph nodes positive, as well as 
information regarding second primary cancers. Cause of death was ascertained through routine matching 
with the Australian National Death Index, with follow up to the 31
st
 December 2009.  
The QCR also holds a record of the most recent admission to every public and private hospital within QLD 
for each cancer patient.  This facilitated a deterministic linkage between the QCR data and the QLD Hospital 
Admitted Patient Data Collection for all admissions on or after the date of diagnosis of breast cancer until 
the end of 2009 as well as any gynaecological surgery that occurred between 1995-2009. Matching was 
performed using a unique hospital record number that was stored in both datasets. Once this link was in 
place we could then identify all admitted episodes of care for each woman during the study period. In 
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particular, we were able to obtain details of breast-cancer related surgical treatment as well as any 
gynaecological surgery (BSO +/-hysterectomy).  Data on selected comorbidities (atherosclerosis, 
cerebrovascular disease, cholesterol (hypercholesterolemia), dementia, deep vein thrombosis, diabetes, heart 
disease, osteoporosis/bone fractures and pulmonary embolism) that were documented during admission were 
also obtained (see Table 1 for definitions).  After the data linkage was completed, de-identified data was 
extracted by the data custodians for analysis.   
 
Surgical procedures 
Relevant gynaecological and breast cancer-related surgical codes are shown in Table 1, classified by type of 
procedure.  For the aim of this study we defined “risk-reducing” gynaecological surgery as those surgical 
procedures that were performed electively at least 30 days prior to a diagnosis of gynaecological cancer.   
Four procedure groups were formed: (i) hysterectomy only (including hysterectomy plus unilateral salpingo-
oophorectomy (USO)); (ii)  BSO only (including two separate USOs); (iii) both hysterectomy and BSO; and 
(iv) neither (including single USO only). Procedures were conservatively classified as “hysterectomy only” 
in situations where it was unclear whether a hysterectomy also involved a USO or BSO (see Table 1).   
Some women with breast cancer did not have a matching hospital treatment record.  The reasons for this are 
unclear, but may include those who received treatment either interstate or overseas.  As we could not be sure 
that these cases did not undergo any risk-reducing gynaecological surgery, they were excluded from the 
study to ensure that they were not incorrectly included in the group who did not have surgery. 
 
Statistical analyses 
Survival time was calculated as the number of days between diagnosis and either death or 31
st
 December 
2009, whichever came first. The follow-up period for each patient was divided between the four risk-
reducing gynaecological surgical procedure groups, depending on type and timing of procedures. For 
instance, if a patient who survived for eight years had a risk-reducing hysterectomy without BSO two years 
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after her breast cancer diagnosis, then the first two years of her follow up were assigned to the group with no 
surgery, while the remaining six years were assigned to the group of “hysterectomy only”.    
Flexible parametric survival models (also known as Royston-Parmar models) were used for this analysis
30, 
31
.  The baseline survival distribution is represented as a restricted cubic spline function in Royston-Parmar 
models. This leads to several advantages over the traditional Cox proportional hazard models, particularly 
the ease with which non-proportional effects can be handled. 
Royston-Parmar models may be fitted using various scales for the restricted cubic spline function, including 
hazards (Weibull models), odds (loglogistic models) and normal (probit models).  A differing number of 
internal “knot points” (where the pieces of the spline function join) can also be defined. The aim is to choose 
the scale and number of knot points which result in the best proportionality assumption for the covariates, 
and is determined by the combination that minimizes the Bayes information criterion statistic.  Significant 
covariates are selected via backward elimination using a multivariable fractional polynomial approach
31
.   
We conducted modelling for all-cause survival, breast-cancer specific survival and survival due to causes 
other than breast cancer.  The analysis of breast-cancer specific survival was further stratified for “pre-
menopausal” and “post-menopausal” women (20-49 years and 50-79 years).  For the all-cause and breast-
cancer specific survival models, the normal scale with 3 degrees of freedom (2 internal knot points) 
provided the best fit, while for non-breast cancer survival the optimum model was on the odds scale also 
with 3 degrees of freedom.   
The main variable of interest was risk-reducing gynaecological procedure group.  Delayed entry survival 
models were utilised to account for the fact that the risk-reducing gynaecological procedure group for an 
individual could alter during their time at risk. Other covariates that were considered included age group at 
diagnosis of first primary breast cancer, Indigenous status, area-based socioeconomic status, locality of 
residence, morphology, tumour size, lymph node ratio, laterality, type of breast cancer surgery, hospital 
type, diagnosis of second primary cancer (breast, gynaecological, and other), and the comorbidities listed 
above.  In addition, significant covariates (p <= 0.20), including risk-reducing  gynaecological procedure 
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group, were tested for time dependency within each model, by fitting interactions between the covariates 
and time using additional spline functions.      
Unadjusted and adjusted estimates of 10-year survival with 95% confidence intervals were calculated.  
Differences in survival by risk-reducing gynaecological procedure group were determined using the model 
coefficients (), with the reference group being “neither hysterectomy nor BSO”.  The significance of the 
overall effect for risk-reducing gynaecological surgery group was also assessed using the Wald test and 
expressed in terms of a chi-square statistic. Individual estimates were only considered significant if p <= 
0.05 for the overall effect.  Adjusted survival curves were produced by averaging the predicted survival 
curve for each subject in a particular stratum.     
Propensity score analysis was retrospectively applied to breast cancer specific survival among younger 
women, in an attempt to minimise selection bias that could have explained survival differences by risk-
reducing gynaecological procedure group 
32, 33
. The propensity score is defined as the probability of 
treatment assignment conditional on observed baseline covariates. Covariates recorded at the time of breast 
cancer diagnosis and known to influence survival were age, tumour size and positive lymph node ratio 
expressed as continuous variables along with categorical groupings for Indigenous status, locality of 
residence and cell type/morphology (as shown in Table 2). Observations were randomly sorted prior to 
matching. Propensity scores for treatment ranged from 0.056 to 0.319 for breast cancer patients aged 20-49 
years.  Those who had some form of risk-reducing gynaecological surgery were matched with three others 
who did not have surgery using nearest neighbour matching without replacement, with a maximum absolute 
difference of 0.01 allowed in the propensity score for each matched pair (one woman was excluded as there 
were only 2 suitable matches). Paired t-tests were used to ensure that there were no biases in the distribution 
of the matching variables between the treated and untreated subjects. 
The survival analysis described above was then repeated for the matched cohort. The optimum Royston-
Parmar model was on the normal scale with 2 degrees of freedom.  Variables used in the matching process 
were not included as covariates; rather, Austin 
34
 suggests that survival models should be stratified on the 
matched groups to account for the matched nature of the cohort.  As it is not possible to stratify a parametric 
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model when the numbers in each strata are so small (n=4), we divided the matched groups into deciles based 
on the propensity score of the treated case, and the model was then stratified by these deciles (n~340 in each 
strata).  
All data analyses were performed using Stata/SE version 12.1 for Windows. Human Research and Ethics 
approval for this study was obtained from the Human Research Ethics Committee at the Royal Brisbane and 
Women’s Hospital (HREC/10/QRBW/425).  
 
Results 
Of the 25,536 patients diagnosed with primary female breast cancer in QLD between 1997 and 2008, 21,067 
(82%) were eligible.  The remaining 4,469 women were excluded due to not having a matching hospital 
record (2,736 cases, 11%), being younger than 20 years or older than 79 years at the time of diagnosis 
(1,726 cases, 7%), or where the basis of diagnosis was either autopsy or death certificate only (7 cases, 
0.03%).  Those who were eligible amassed a total of 119,340 years at risk (median follow-up of 4.6 years; 
interquartile range 3.0 to 8.6 years). Overall, 3,165 (15%) women died during follow-up, including 2,195 
(10%) from breast cancer. Key demographic, clinical and treatment characteristics of the study cohort are 
summarised in Table 2.   
Overall, 1,426 women (7%) underwent risk-reducing gynaecological surgery (Table 2). However, this varied 
by age, with 13% of breast cancer patients in the 20-39 age group having risk-reducing gynaecological 
surgery compared to only 3% who were aged 70-79 years old at diagnosis. Apart from younger age, women 
were more likely to have risk-reducing gynaecological surgery if they were non-Indigenous, diagnosed with 
infiltrating ductal and lobular carcinoma, if they had positive axillary lymph nodes and attended both a 
public and private hospital for breast cancer treatment. Women who lived in a major city, or who had 
cerebrovascular disease, diabetes mellitus or heart disease were less likely to undergo risk-reducing 
gynaecological surgery. 
A total of 171 women developed gynaecological cancer subsequent to breast cancer, all in women who did 
not have risk-reducing gynaecological surgery (p = 0.006, Table 2). Of those, 23 cancers developed in 
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premenopausal women (including 8 ovarian cancers), and 148 in postmenopausal women, respectively. In 
addition, 1,006 women developed new primary breast cancers and 868 were diagnosed with at least one 
other cancer following their initial breast cancer. There were no significant differences in the distribution of 
subsequent new breast cancers (p = 0.094) or other cancers (p = 0.123) by final risk-reducing surgery status.  
After adjustment for the covariates listed in Table 3, breast cancer patients who had both a hysterectomy and 
BSO had a significantly higher survival rate 10 years after diagnosis for all causes of mortality (85%) 
compared to those who did not have any risk-reducing gynaecological surgery ( 79%, p = 0.002; Table 4 and 
Figure 1).  The differential was similar for breast cancer specific mortality (adjusted 10 year survival of 89% 
and 85% respectively, p = 0.005).  However, for both all cause and breast cancer specific mortality, there 
was no statistically significant evidence of a survival benefit among women who had either a risk-reducing 
hysterectomy only or BSO only compared to the non-surgery group.  There was also no disparity in survival 
by risk-reducing gynaecological surgery group due to causes other than breast cancer, including other types 
of cancer (Table 4 and Figure 1), or for non-cancer deaths only (data not shown). 
Further analysis by age at diagnosis for breast cancer specific survival indicated that the improvement in 
prognosis among those who had both a hysterectomy and BSO was only significant among younger women 
(Table 5, Figure 2).  Premenopausal women (20-49 age group) had significantly better survival after 10 
years (93%) compared to women of the same age who had neither procedure (83%, p = 0.001).   In contrast, 
there were no significant differences in breast cancer specific survival by type of risk-reducing 
gynaecological surgery for women 50-79 years. 
When we repeated the breast cancer specific survival analysis for women aged 20-49 using the matched 
sample, results were similar (Supplementary Table).  Again, a significant survival advantage was only seen 
for women who had hysterectomy plus BSO compared to those who did not have any risk-reducing 
gynaecological surgery (p=0.002).      
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Discussion 
In premenopausal women diagnosed with primary breast cancer, risk-reducing hysterectomy and BSO 
increased breast cancer-specific survival from 83% to 93% after 10 years. This effect remained after 
matching for some characteristics that are known to influence prognosis. In contrast, no significant survival 
benefit of risk-reducing gynaecologic surgery was observed for postmenopausal women.  
It is generally accepted that estrogen can stimulate breast cancer growth 
7
. Endocrine treatments suppressing 
circulating estrogens via action on the hypothalamic-pituitary-ovarian axis improve survival outcomes in 
premenopausal hormone receptor-positive breast cancer patients 
28
. Ovarian ablation either by radiation 
treatment or through surgical removal of the ovaries has been advocated in the past but has become less 
commonly used due to the availability of a modern array of non-invasive endocrine treatment options 
35
. 
These modern treatments are widely thought to be at least as effective as surgical removal of the ovaries 
36
.  
Our findings may provide a challenge to this belief.  The main effect of hysterectomy and BSO on breast 
cancer-specific survival limited to premenopausal women suggests that hysterectomy plus BSO provides 
advantage by combined hormone ablation 
28
. In Australia, endocrine treatment is well accepted and 
established in hormone receptor-positive breast cancer patients. Before the introduction of anti-estrogenic 
medication in the late 1970s, ovarian ablation was performed through surgical removal of the ovaries, 
radiation treatment, GnrH analogues and chemotherapy. Silencing of the ovaries using radiation treatment 
resulted in a 25% benefit compared to patients who had no adjuvant treatment 
35
. As has been highlighted 
elsewhere 
35
, we can also assume that BSO had a smaller impact in terms of hormonal ablation on breast 
cancer patients who were given chemotherapy. However, chemotherapy is variable in its effectiveness of 
silencing the ovaries with reported rates ranging between 10-98% 
37, 38
 and BSO may thus have an effect in 
addition to either chemotherapy or hormonal treatment. While the current study does not answer this 
important question, a three-arm randomised controlled clinical trial (SOFT) that assigned patients to receive 
either oral tamoxifen (control) or tamoxifen plus ovarian function suppression through triptorelin, surgical 
oophorectomy, or ovarian irradiation is in progress 
39
.  It remains to be researched further as to why only 
patients who had a BSO plus hysterectomy benefitted from improved survival but patients who had a BSO 
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or hysterectomy alone did not. On the other hand, a pattern of care study compared Australian (Perth, 
Western Australia), Canadian and Scottish treatment patterns based on hospital data.  In Australia, 29% of 
breast cancer patients received chemotherapy, and 59% received endocrine treatment. These authors 
assessed the treatment received compared to current guidelines, and found that in all jurisdictions patients 
with stage II, node positive, hormone receptor negative tumours and stage IV hormone receptor positive 
tumours may not receive chemotherapy to the full extend recommended, however no shortfalls in endocrine 
treatment were noted. Indeed, Australian treatment was exceeding “optimal” levels 40 , however these data 
are likely reflecting the prescribed rather than the actual received medication. Bell et al 
41
 assessed self-
reported Tamoxifen or Aromotase use in 1,683 women for five years after diagnosis of a hormone receptor-
positive breast cancer in Victoria between 2004-2006. It found that 7.8% of women self-reported no 
endocrine medication, 10.2% reported using oral adjuvant endocrine therapy up to two years, 15.6% three 
years and two-thirds of women for at least 4 years. This indicates that while coverage of endocrine treatment 
in Australia is good, there may be a significant proportion of women who do not start endocrine treatment, 
or do not persist with such treatment for the required length of time, and could therefore particularly benefit 
from risk-reducing surgery.  
We did not find any difference in survival after 10 years from causes other than breast cancer by risk-
reducing gynaecological surgery status.  Our results therefore indirectly suggest that the effect of combined 
risk-reducing surgery on menopause-related risk factors such as cardiovascular health was minimal and 
appear to have been heavily outweighed by the survival advantages due to a decrease in breast cancer-
specific mortality. However, a significantly higher proportion of women in the “no surgery” group were 
identified as having cerebrovascular and/or heart disease comorbidities, and this may be part of the reason 
why they were not offered risk-reducing surgery; only women with low risk of cardiovascular disease may 
have elected for prophylaxis. 
While population-based studies reflect “real” world scenarios, they do not provide definitive proof of 
mechanism of action leading to the observed outcomes. Overall, within the 10-year observation period of 
our study, 171 women who did not have risk-reducing surgery developed gynaecological cancer. Of those 
only 23 patients were premenopausal (14 developed uterine cancer, eight ovarian cancers). In contrast, none 
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of the women who had risk-reducing gynaecological surgery developed gynaecological cancer. The 
relatively small number of prevented cancers in premenopausal women indicates that it is unlikely that the 
significant survival advantage among premenopausal women is mainly a result of surgical prophylaxis of 
these potential gynaecological cancers. Our data did not provide details of women’s BRCA1/2 status and 
family history. Given that only eight premenopausal breast cancer patients who did not have risk-reducing 
surgery developed a new primary ovarian cancer during the observation period, it is also unlikely that the 
results were largely driven by patients at high risk due to genetic mutations.  However, the possibility 
remains that the majority of those who were BRCA1/2 positive may have been offered risk-reducing 
prophylactic gynaecological surgery. 
As noted in the introduction, for women from the general population, the effect of hysterectomy plus BSO 
on overall survival is controversial. The prospective Nurses’ Health Study cohort study included 29,380 
women who had a hysterectomy for benign disease (mean age at surgery = 45 years; 28 years follow-up) 
21-
23, 42
. Women who additionally had a BSO had significant reductions in ovarian cancer incidence and 
mortality and reduced risk of breast cancer incidence for premenopausal women following hysterectomy and 
BSO. However, BSO at the time of hysterectomy was associated with increased overall mortality in women 
younger than 50 years who never used estrogen therapy, and at no time was BSO associated with increased 
overall survival 
42, 43
.  
The prospective Women’s Health Initiative Observational Study included 25,448 women who had a 
hysterectomy for a benign condition (average age 49 years; follow-up eight years) 
20
. Women in this study 
were initially invited to participate in the Women’s Health Initiative randomized trial that evaluated 
postmenopausal hormone therapy, but were either found ineligible or declined participation in the trial. 
Women who had a BSO during hysterectomy had significant reductions in ovarian cancer incidence and 
mortality compared with women who conserved their ovaries. In contrast to the Nurses’ Health Study, breast 
cancer incidence was not reduced for women who had a BSO, nor was there an increased risk in all cause 
mortality among pre- or postmenopausal women who had a BSO at the time of hysterectomy.  
13 
 
The retrospective population-based Mayo Clinic Cohort Study of Oophorectomy and Aging enrolled 2365 
women who underwent USO or BSO for benign disease in conjunction with hysterectomy 
26
. Every member 
of the cohort was matched by age to a referent woman in the same population who had not undergone 
oophorectomy. The median age at time of surgery was 44 years among premenopausal women who had a 
BSO and 62 years among postmenopausal women (average follow-up 25 years). Overall mortality was 
significantly higher in women who had received prophylactic BSO before the age of 45 years compared to 
referent women, while having a BSO made no difference to all-cause mortality in postmenopausal women.  
The differences in outcomes of these studies compared to the results presented here are likely explained by 
the different groups of women enrolled. In particular, the three studies outlined above enrolled women from 
the general population who required a hysterectomy for benign conditions, whereas our study enrolled only 
patients diagnosed with primary breast cancer. The latter population clearly has a significantly increased risk 
of death, as well as a significantly increased risk of developing gynaecological cancers 
9
.  
While this population-based study uses innovative new statistical models, which better handle non-
proportional effects, the design employed within the present study inherits limitations that need to be 
acknowledged. First, the follow-up duration available to us was limited to a maximum of 10 years, due to 
the fact that health administrative data became available in Queensland only in 1997. Secondly, we were 
unable to determine whether pre-existing comorbidities were present at the time of breast cancer diagnosis; 
in most cases these could only be subsequently ascertained if they were recorded in the hospital chart during 
treatment. On that basis we were unable to take comorbidities into account in the propensity score matching, 
which leaves open the possibility of some bias remaining in the matched cohort analysis. There was also 
some potential for misclassification of women regarding the prophylactic gynaecological surgery groups due 
to procedures that may have been performed prior to matched records being available.  Further, reasons for 
surgery were not recorded in the information provided by Queensland Health.  Information on postoperative, 
adjuvant treatment as well as hormonal replacement therapy (HRT) could not be obtained because these 
treatments do not require a hospital admission. Finally, data on hormone receptor status were not available, 
which would have been valuable to examine if prophylactic gynaecological surgery was effective in 
14 
 
hormone-receptor positive patients only, or if the effect also extended to hormone-receptor negative breast 
cancer patients. Similarly we were not able to obtain patients’ BRCA status.  
In summary, the results indicate that premenopausal women with breast cancer may benefit from 
hysterectomy plus BSO in addition to the ovarian ablation provided by the adjuvant treatment they 
commonly receive. While the results of the present study are promising and important, the decision to 
undergo prophylactic gynaecological surgery obviously has major ramifications for younger women. 
Therefore, our findings need to be replicated in at least one other independent dataset and tested in a 
randomised trial before current treatment recommendations for premenopausal women diagnosed with 
breast cancer are reconsidered.  
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Table 1: ICD-9-CM and ICD-10-AM procedure and disease codes 
 
 
Type of surgery/ 
disease 
 
 
ICD-9-CM codes 
 
 
ICD-10-AM codes 
Gynaecological procedures  
Hysterectomy and BSO  35653-03, 35673-01, 35753-01, 35756-02 
Hysterectomy and USO  35653-02, 35673-00, 35753-00, 35756-01 
Hysterectomy only 68.3-68.9 35653-00, 35653-01, 35653-04
a
, 35657-00, 
35661-00
a
, 35664-00
a
, 35664-01
a
, 35667-00
a
, 
35667-01
a
, 35670-00
a
, 35673-02
a
, 35750-00, 
35753-02
a
, 35756-00, 35756-03
a
, 90443-00, 
90448-00, 90448-01, 90448-02
a
 
BSO only 65.51, 65.52, 65.61, 65.62 35638-03, 35638-12, 35717-01, 35717-04 
USO only 65.3, 65.4 35638-02, 35638-11, 35638-13, 35713-07,  
35713-11, 35717-05 
Breast cancer related procedures 
Breast-conserving 85.20-85.23 30342-00, 30342-01, 30346-00, 30346-01,  
30347-00, 30348-00, 30350-00, 30350-01,  
31500-00, 31515-00. 
Mastectomy 85.41-85.48 30338-00, 30338-01, 30338-02, 30351-00,  
30351-01, 30353-00, 30353-01, 30353-02,  
30354-00, 30354-01, 30356-00, 30356-01,  
31518-00, 31518-01, 31524-00, 31524-01,  
30359-00, 30359-01, 30359-02, 30359-03,  
30359-04, 30359-05, 30359-06, 30359-07 
Comorbidities 
Atherosclerosis 440 I70 
Cerebrovascular disease 430-438 G45-46, I60-I69 
Hypercholesterolemia 272 E78.0 
Dementia  290 F00-F01 
Deep vein thrombosis 451.1-451.9 I80.2-I80.9 
Diabetes  250 E10-E14 
Heart Disease 401-404, 410-411, 413-414, 
428 
I10-I12, I20-I22, I24-I25, I50 
Osteoporosis/ 
bone fractures 
733 M80-81 
Pulmonary embolism 415.1 I26 
Abbreviations:  BSO = bilateral-salpingo oophorectomy; USO = unilateral-salpingo oophorectomy. 
Notes: a. These procedures may also involve a USO or BSO.  They were assigned to the category “Hysterectomy only”  
  for the main analysis, and sensitivity analyses were subsequently performed to determine what effect  
  assigning these procedures to the categories “Hysterectomy and USO” or “Hysterectomy and BSO” would  
  have on the results. 
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Table 2: Cohort of first primary breast cancer patients diagnosed in Queensland  
by type of prophylactic gynaecological surgerya, 1997-2008 
 Total 
cohort  
 
Neither 
Hyst. 
 only 
BSO  
only 
 
Both 
Number of eligible women 21,067 19,650 634 286 497 
Row % 100.0 93.3 3.0 1.4 2.4 
Total years at risk 119,340 110,810 3,559 1,622 3,349 
Median years at risk 5.4 5.4 5.4 5.5 7.1 
 n Row  % Row  % Row  % Row  % 
Age group at diagnosis      
 20-39 1,434 87.4 3.6 5.0 4.0 
 40-49 4,606 88.5 5.1 2.4 4.0 
 50-59 6,257 93.8 2.9 1.1 2.3 
 60-69 5,347 95.8 2.1 0.5 1.5 
 70-79 3,423 97.3 1.7 0.2 0.9 
 Chi-squared = 491.2; d.f. = 12; p < 0.001   
Indigenous status      
 Indigenous 259 94.2 1.9 1.9 1.9 
 Non-Indigenous 18,753 93.1 3.1 1.4 2.4 
 Not stated 2,055 94.8 2.7 0.7 1.7 
 Chi-squared = 13.85; d.f. = 6; p = 0.031   
Area-based socioeconomic status      
 Most disadvantaged 2,586 93.4 3.0 1.2 2.4 
 Middle SES 14,887 93.3 3.0 1.4 2.3 
 Most advantaged 3,525 93.1 3.1 1.0 2.7 
 Unknown 69 92.8 ** ** ** 
 Chi-squared = 12.33; d.f. = 9; p = 0.195   
Locality of residence      
 Major city 12,683 93.8 2.8 1.3 2.1 
 Inner regional 4,597 92.6 3.2 1.3 2.9 
 Other 3,720 92.4 3.4 1.7 2.5 
 Unknown 67 92.5 ** ** ** 
 Chi-squared = 23.31; d.f. = 9; p = 0.006   
Morphology      
 Infiltrating duct carcinoma (8500-3) 15,813 93.1 3.1 1.4 2.3 
 Lobular carcinoma (8520-3) 2,488 94.0 2.7 1.0 2.4 
 Infiltrating duct and lobular carcinoma (8522-3) 763 91.6 2.9 2.2 3.3 
 Other 2,003 94.5 2.6 0.9 2.0 
 Chi-squared = 18.12; d.f. = 9; p = 0.034   
Tumour size      
 <=20mm 12,373 93.5 2.9 1.2 2.4 
 21mm-50mm 6,741 92.6 3.4 1.6 2.4 
 >50mm 1,208 93.5 2.8 1.3 2.3 
 Not recorded 745 95.4 2.1 0.8 1.6 
 Chi-squared = 14.43; d.f. = 9; p = 0.108   
Lymph node status      
 No lymph nodes excised 2,485 95.4 2.0 1.0 1.6 
 No positive lymph nodes 11,230 93.4 3.0 1.3 2.4 
 At least 1 positive lymph node 6,850 92.2 3.5 1.7 2.7 
 Not recorded 502 94.4 3.0 1.0 1.6 
 Chi-squared = 34.33; d.f. = 12; p < 0.001   
Laterality      
 Left 10,361 93.0 3.1 1.5 2.4 
 Right 10,618 93.5 3.0 1.2 2.3 
 Not stated 88 94.3 ** 0.0 ** 
 Fisher’s exact test; p = 0.563   
Type of breast cancer surgery      
 Breast conserving surgery 13,395 93.6 2.9 1.3 2.2 
 Mastectomy 6,179 93.1 3.0 1.4 2.5 
 No curative surgery recorded 1,493 91.4 3.9 1.6 3.1 
 Chi-squared = 11.12; d.f. = 6; p = 0.085   
cont. 
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Table 2 (cont.): Cohort of first primary breast cancer patients diagnosed in Queensland  
by type of prophylactic gynaecological surgerya, 2000-2008 
 Total 
cohort  
 
Neither 
Hyst. 
 only 
BSO  
only 
 
Both 
Number of eligible women 21,067 19,650 634 286 497 
Row % 100.0 93.3 3.0 1.4 2.4 
 n Row  % Row  % Row  % Row  % 
Hospital type
b
      
 Public 9,208 93.8 2.7 1.3 2.1 
 Private 11,141 93.0 3.2 1.3 2.5 
 Both 247 70.0 12.6 5.7 11.7 
 Unknown/Not applicable 471 100.0 0.0 0.0 0.0 
 Chi-squared = 216.61; d.f. = 6; p < 0.001
c
   
Multiple primary cancers      
 Breast cancer - Yes 1,006 91.7 3.1 2.0 3.2 
  - No 20,061 93.4 3.0 1.3 2.3 
 Chi-squared = 6.40; d.f. = 3; p = 0.094   
 Gynaecological cancer - Yes 171 100.0 0.0 0.0 0.0 
  - No 20,896 93.2 3.0 1.4 2.4 
 Fisher’s exact test; p < 0.001   
 Other cancer - Yes 868 93.0 2.9 0.8 3.3 
  - No 20,199 93.3 3.0 1.4 2.3 
 Chi-squared = 5.78; d.f. = 3; p = 0.123   
Other reported diseases and conditions      
 Atherosclerosis - Yes 149 97.3 ** ** 0.0 
  - No 20,918 93.2 3.0 1.4 2.4 
 Fisher’s exact test; p = 0.104   
 Cerebrovascular disease - Yes 461 97.2 ** ** 1.5 
  - No 20,606 93.2 3.1 1.4 2.4 
 Chi-squared = 12.63; d.f. = 3; p = 0.006   
 Hypercholesterolemia  - Yes 566 95.6 2.7 ** 1.2 
     - No 20,501 93.2 3.0 1.4 2.4 
 Chi-squared = 6.62; d.f. = 3; p = 0.085   
 Dementia - Yes 83 100.0 0.0 0.0 0.0 
  - No 20,984 93.2 3.0 1.4 2.4 
 Fisher’s exact test; p = 0.167   
 Deep vein thrombosis - Yes 368 92.4 4.3 ** 2.7 
  - No 20,699 93.3 3.0 1.4 2.4 
 Chi-squared = 4.29; d.f. = 3; p = 0.232   
 Diabetes - Yes 1,829 95.1 2.4 0.7 1.9 
  - No 19,238 93.1 3.1 1.4 2.4 
 Chi-squared = 12.51; d.f. = 3; p = 0.006   
 Heart disease - Yes 2,052 95.3 2.2 0.5 1.9 
  - No 19,015 93.1 3.1 1.5 2.4 
 Chi-squared = 19.77; d.f. = 3; p < 0.001   
 Osteoporosis or bone fractures - Yes 320 95.0 2.5 ** 2.2 
  - No 20,747 93.2 3.0 1.4 2.4 
 Chi-squared = 3.04; d.f. = 3; p = 0.386   
 Pulmonary embolism - Yes 345 95.4 2.3 ** 1.4 
  - No 20,722 93.2 3.0 1.4 2.4 
 Chi-squared = 2.57; d.f. = 3; p = 0.463   
Abbreviations and symbols:  Hyst. only = hysterectomy only; d.f. = degrees of freedom; BSO = bilateral-salpingo oophorectomy; ** 
= data withheld - cell count < 5.  
Notes: a. The cohort was categorised depending on the type of prophylactic gynaecological surgery performed as at  
     the end of the follow-up period for each woman.  
 b. Includes hospital/s were the patient was treated for breast cancer and/or where prophylactic gynaecological 
     surgery was performed. 
 c. Chi-square test excludes the category “Unknown/Not applicable”. 
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Table 3: Covariates included in flexible parametric survival models  
by cause of death and age group  
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 c
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Prophylactic gynaecological procedure * * * * * * 
Age group * * * * **  
Indigenous status * * * * *  
Area-based socioeconomic status * *    * 
Locality of residence * * * * *  
Morphology ** * * * *  
Tumour size ** ** * ** *  
Lymph node ratio ** ** * ** **  
Laterality * *  *   
Type of breast cancer surgery * * * ** * * 
Hospital type * * * * * * 
Second primary breast cancer *   ** *  
Gynaecological cancer ** *  * **  
Other cancer  ** * * * ** * 
Atherosclerosis ** *  *   
Cerebrovascular disease **    * * 
Hypercholesterolemia * * * * *  
Dementia **    **  
Deep vein thrombosis ** ** * **  ** 
Diabetes ** * * * ** * 
Heart disease ** *  ** *  
Osteoporosis or bone fractures * * * * * * 
Pulmonary embolism ** ** * * * * 
Notes: * = included in model; ** = included in model as a time dependent covariate.   
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Table 4:  Ten-year survival estimates by cause of death and  
prophylactic gynaecological surgery group 
 
 
Prophylactic 
gynaecological  
surgical procedure 
 
 
 
n
a
 
Unadjusted  
10-year survival 
estimates 
(95% CI) 
Adjusted  
10-year survival 
estimates 
(95% CI) 
  
Model  
coefficients 
(, 95% CI) 
 
 
 
p 
All cause mortality 
Neither 20,650 76.4 (75.6-77.2) 78.5 (77.8-79.3) 1.00  
Hysterectomy only 650 79.2 (74.4-83.3) 79.7 (75.9-83.5) -0.04 (-0.21,+0.13) 0.610 
BSO only 287 76.2 (68.1-83.0) 78.4 (72.2-84.6) +0.01 (-0.25,+0.28) 0.914 
Hysterectomy and BSO 497 84.4 (79.8-88.2) 85.0 (81.4-88.6) -0.31 (-0.50,-0.11) 0.002 
Overall effect:  Chi-square = 9.84; Degrees of freedom = 3; p = 0.020 
Breast cancer specific mortality  
Neither 20,650 84.3 (83.6-85.0) 84.0 (83.4-84.7) 1.00  
Hysterectomy only 650 84.6 (80.2-88.2) 85.1 (81.7-88.5) -0.05 (-0.24,+0.13) 0.581 
BSO only 287 79.9 (72.0-86.2) 83.9 (78.6-89.3) +0.01 (-0.26,+0.29) 0.929 
Hysterectomy and BSO 497 89.2 (85.1-92.4) 89.3 (86.2-92.5) -0.31 (-0.52,-0.09) 0.005 
Overall effect:  Chi-square = 8.02; Degrees of freedom = 3; p = 0.046 
Non-breast cancer mortality  
Neither 20,650 90.4 (89.7-91.0) 92.5 (92.0-93.0) 1.00  
Hysterectomy only 650 94.2 (90.3-96.6) 92.8 (89.6-95.9) -0.05 (-0.67,+0.56) 0.862 
BSO only 287 96.6 (90.1-98.9) 94.2 (88.8-99.6) -0.37 (-1.64,+0.90) 0.570 
Hysterectomy and BSO 497 94.8 (91.1-97.0) 93.1 (89.9-96.3) -0.13 (-0.77,+0.52) 0.701 
Overall effect:  Chi-square = 0.49; Degrees of freedom = 3; p = 0.921 
Abbreviations:  BSO = bilateral-salpingo oophorectomy; 95% CI = 95% confidence interval. 
 
Notes: a. Includes all women who contributed survival time to that prophylactic surgical procedure.  An individual  
  woman may contribute survival time to more than one prophylactic surgical procedure.   
 b. The covariates used to adjust each model are listed in Table 3. 
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Table 5:  Ten-year survival estimates for breast cancer specific mortality by  
type of prophylactic gynaecological surgery and age group 
 
 
Prophylactic 
gynaecological  
surgical procedure 
 
 
 
n
a
 
Unadjusted  
10-year survival 
estimates 
(95% CI) 
Adjusted  
10-year survival 
estimates 
(95% CI) 
  
Model  
coefficients 
(, 95% CI) 
 
 
 
p 
Breast cancer specific mortality – 20-49 years old 
Neither 5,904 83.2 (81.8-84.5) 83.0 (81.7-84.3) 1.00  
Hysterectomy only 298 82.6 (75.4-88.3) 82.7 (76.8-88.5) +0.03 (-0.24,+0.31) 0.812 
BSO only 184 78.8 (68.9-86.6) 83.6 (76.7-90.5) -0.01 (-0.34,+0.32) 0.949 
Hysterectomy and BSO 244 92.5 (87.0-96.0) 92.9 (88.9-97.0) -0.61 (-0.97,-0.26) 0.001 
Overall effect:  Chi-square = 11.58; Degrees of freedom = 3; p = 0.009 
Breast cancer specific mortality – 50-79 years old 
Neither 14,746 84.8 (83.9-85.5) 84.6 (83.9-85.4) 1.00  
Hysterectomy only 352 85.8 (80.1-90.3) 86.9 (82.8-91.1) -0.13 (-0.38,+0.12) 0.317 
BSO only 103 82.8 (69.7-91.6) 84.0 (74.7-93.3) +0.04 (-0.45,+0.52) 0.878 
Hysterectomy and BSO 253 86.7 (80.5-91.4) 86.7 (82.0-91.3) -0.11 (-0.39,+0.16) 0.425 
Overall effect:  Chi-square = 1.63; Degrees of freedom = 3; p = 0.652 
Abbreviations:  BSO = bilateral-salpingo oophorectomy; 95% CI = 95% confidence interval. 
 
Notes: a. Includes all women who contributed survival time to that prophylactic surgical procedure.  An individual  
  woman may contribute survival time to more than one prophylactic surgical procedure.   
 b. The covariates used to adjust each model are listed in Table 3. 
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Supplementary Table:  Ten-year survival estimates in the propensity score matched cohort for 
breast cancer specific mortality among women aged 20-49 years by  
by type of prophylactic gynaecological surgery  
 
 
Prophylactic 
gynaecological  
surgical procedure 
 
 
 
n
a
 
Unadjusted  
10-year survival 
estimates 
(95% CI) 
Adjusted  
10-year survival 
estimates 
(95% CI) 
  
Model  
coefficients 
(, 95% CI) 
 
 
 
p 
Neither 2,704 83.1 (81.0-85.2) 83.4 (81.5-85.5) 1.00  
Hysterectomy only 298 81.6 (74.2-87.5) 81.2 (74.7-87.7) +0.12 (-0.15,+0.38) 0.390 
BSO only 183 77.8 (67.8-85.7) 80.8 (72.9-88.7) +0.13 (-0.19,+0.45) 0.423 
Hysterectomy and BSO 244 92.2 (86.6-95.8) 92.6 (88.3-96.8) -0.53 (-0.87,-0.19) 0.002 
Overall effect:  Chi-square = 11.19; Degrees of freedom = 3; p = 0.011 
Abbreviations:  BSO = bilateral-salpingo oophorectomy; 95% CI = 95% confidence interval. 
 
Notes: a. Includes all women who contributed survival time to that prophylactic surgical procedure.  An individual  
  woman may contribute survival time to more than one prophylactic surgical procedure.   
 b. The covariates used to adjust each model are listed in Table 3. 
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Figure 1:  Adjusted survival curves by cause of death and  
prophylactic gynaecological surgery groupa,b 
Abbreviations:  BSO = bilateral-salpingo oophorectomy. 
Notes: a. An individual woman may contribute survival time to more than one prophylactic surgical procedure group. 
 b. The covariates used to adjust the model are listed in Table 3. 
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Figure 2:  Adjusted breast cancer specific survival curves by type of prophylactic gynaecological 
surgical procedure and age groupa,b 
Abbreviations:  BSO = bilateral-salpingo oophorectomy. 
Notes: a. An individual woman may contribute survival time to more than one prophylactic surgical procedure group. 
 b. The covariates used to adjust the model are listed in Table 3 
 
 
